OD designation doesn't provide any revenue. There are other benefits in reducing the overall time to get an outcome from the FDA. If a PRV is granted that has a $ figure (about 100m USD) but those are granted only after a successful NDA in the US. The PRV is worth approximately that value, given recent sales. As a point of comparison Acadia is sitting on a PRV and NEU is entitled to 1/3 of its value (33m AUD) but NEU will also get another PRV for NNZ-2591 for Phelan McDermid Syndrome if they are ultimately successful with Phase 3.
None of this is applicable to TGA/Australian approval.
- Forums
- ASX - By Stock
- NTI
- Ann: Phase II/III autism trial shows further benefits
Ann: Phase II/III autism trial shows further benefits, page-12
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
|
|||||
Last
7.1¢ |
Change
-0.005(6.58%) |
Mkt cap ! $72.23M |
Open | High | Low | Value | Volume |
7.6¢ | 7.8¢ | 6.9¢ | $135.0K | 1.833M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27000 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.1¢ | 33439 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 27000 | 0.070 |
2 | 46286 | 0.069 |
2 | 41617 | 0.068 |
1 | 25000 | 0.067 |
4 | 258292 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.071 | 33439 | 1 |
0.073 | 172720 | 1 |
0.075 | 37501 | 3 |
0.076 | 66000 | 1 |
0.077 | 42000 | 1 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online